1. Home
  2. INKT vs RNLX Comparison

INKT vs RNLX Comparison

Compare INKT & RNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INKT
  • RNLX
  • Stock Information
  • Founded
  • INKT 2017
  • RNLX 2018
  • Country
  • INKT United States
  • RNLX United States
  • Employees
  • INKT N/A
  • RNLX N/A
  • Industry
  • INKT Medicinal Chemicals and Botanical Products
  • RNLX Medical Specialities
  • Sector
  • INKT Health Care
  • RNLX Health Care
  • Exchange
  • INKT Nasdaq
  • RNLX Nasdaq
  • Market Cap
  • INKT 41.3M
  • RNLX 32.8M
  • IPO Year
  • INKT 2021
  • RNLX 2020
  • Fundamental
  • Price
  • INKT $0.88
  • RNLX $0.29
  • Analyst Decision
  • INKT Strong Buy
  • RNLX
  • Analyst Count
  • INKT 1
  • RNLX 0
  • Target Price
  • INKT $9.00
  • RNLX N/A
  • AVG Volume (30 Days)
  • INKT 94.3K
  • RNLX 5.0M
  • Earning Date
  • INKT 08-08-2024
  • RNLX 05-15-2024
  • Dividend Yield
  • INKT N/A
  • RNLX N/A
  • EPS Growth
  • INKT N/A
  • RNLX N/A
  • EPS
  • INKT N/A
  • RNLX N/A
  • Revenue
  • INKT N/A
  • RNLX $2,221,000.00
  • Revenue This Year
  • INKT N/A
  • RNLX $48.40
  • Revenue Next Year
  • INKT N/A
  • RNLX $104.00
  • P/E Ratio
  • INKT N/A
  • RNLX N/A
  • Revenue Growth
  • INKT N/A
  • RNLX N/A
  • 52 Week Low
  • INKT $0.75
  • RNLX $0.22
  • 52 Week High
  • INKT $1.96
  • RNLX $3.66
  • Technical
  • Relative Strength Index (RSI)
  • INKT 43.01
  • RNLX 40.38
  • Support Level
  • INKT $1.00
  • RNLX $0.28
  • Resistance Level
  • INKT $1.23
  • RNLX $0.35
  • Average True Range (ATR)
  • INKT 0.11
  • RNLX 0.04
  • MACD
  • INKT 0.00
  • RNLX 0.01
  • Stochastic Oscillator
  • INKT 12.28
  • RNLX 22.90

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.

About RNLX Renalytix plc

Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the common and costly chronic medical conditions globally. The company's product is KidneyIntelX which is being designed to make improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.

Share on Social Networks: